Condition: Non Small Cell Lung Cancer · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
This is a clinical study on the efficacy and safety of TQB2450 injection combined with chemotherapy or anlotinib hydrochloride capsule in the perioperative treatment of resectable non-small cell lung cancer. The part I study was planned to enroll 58 subjects, 1:1 randomized into two cohorts. The treatment regimen was as follows: Cohort 1: 3-4 cycles of TQB2450 combined with chemotherapy, surgery should be performed 4-6 weeks after the last administration, and TQB2450 therapy should be continued for 1 year after surgery. Cohort 2: 4 cycles of TQB2450 combined with 3 cycles of anlotinib hydrochloride capsule. Surgery was performed 4-6 weeks after the last dose and continued for 1 year starting 4 weeks after surgery.
This description comes directly from the study's public registry record.
Shugeng Gao, Doctor · +86 13901362568 · 13901362568@139.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital of Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Chaoyang Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Chest Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Recruiting |
| Weifang People's Hospital | Weifang, Shandong, China | Recruiting |
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Shanxi Cancer Hospital | Taiyuan, Shanxi, China | Recruiting |
| Tianjin Medical University General Hospital | Tianjin, Tianjin Municipality, China | Not Yet Recruiting |
| Tianjin Chest Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05913089